IPA: ImmunoPrecise Antibodies : Evolving the Intersection of AI, Data and Biology for Drug Discovery

Evolving the Intersection of AI, Data and Biology for Drug Discovery. Spring 2025 | NASDAQ:IPA ©2025 ImmunoPrecise Antibodies LTD. All rights reserved. IPA is a trademark of ImmunoPreciseAntibodies LTD. BioStrand is an independently operating subsidiary of BioStrand, BV. LENS ai and HYFTS are trademarks of BioStrand, BV. Capital structure overview (all values in CAD unless otherwise noted) SHARE DATA (as of March 27, 2025, $ in USD) Shares Outstanding 45,765,118 Share Price USD $0.44 Market Cap USD $20,136,652 BALANCES (as of March 27, 2025) Unrestricted Cash $12.9 million FINANCIAL DATA ($ in 000's) Q3 FY25 FY24 FY23 Revenue (CRO) 17,539 24,518 20,665 Gross Margin 9,088 12,053 11,563 Cash Provided 9,601 (4,788) (22,421) (Used) WARRANTS (as of March 27, 2025) WEIGHTED WEIGHTED FUTURE CASH BALANCE AVERAGE AVERAGE LIFE OPPORTUNITY EXERCISE PRICE REMAINING (YRS) 130,111 $24.14 1.01 $3,140,880 56,650 $1.44 3.85 $81,576 OPTIONS (as of March 27, 2025) WEIGHTED WEIGHTED AVERAGE BALANCE AVERAGE LIFE EXERCISE REMAINING (YEARS) PRICE Exercisable 1,389,165 $7.50 2.66 Unvested 723,417 $1.39 8.88 Total 2,112,582 $5.41 4.79 NASDAQ:IPA | ir.ipatherapeutics.com | www.ipatherapeutics.com Partner with the best "We tried 7 different AI companies and could not validate any of the work, until IPA...we've validated 100% of the results from LENS ai " - Top 10 Global Pharma Partner "IPA is known for taking the toughest "LENS ai is the OpenAI of the life sciences. programs and knocking them out of the park" Every pharma company develops drugs. - Top 5 Global Pharma Partner IPA is the company that EVERYONE will use. - Multi-Billion Dollar Tech Partner IPA works with 19 of top 20 pharma - global partners include: NASDAQ:IPA | ir.ipatherapeutics.com | www.ipatherapeutics.com Leadership Jennifer Bath, Ph.D.: Frédéric Chabot: Dr. Ingrid Brands, MD, Ph.D.: Dr. Dirk Van Hyfte MD, Ph.D.: Chief Executive Officer Head Corp Development Co-Founder, BioStrand Co-Founder, BioStrand Visionary executive in Business strategist with Experienced leader in biotech Pioneering expert in AI-driven drug biotechnology and therapeutics, deep expertise in biotech operations and strategic growth, discovery and computational biology, specializing in therapeutic and investments, AI-driven market ensuring seamless execution of AI- leading the integration of HYFT prophylactic drug development, expansion, and corporate powered discovery and laboratory technology with large-scale AI AI-driven biologics, and infectious finance. Drives strategic integration. Expertise in data-driven models. disease. Spearheads LENS ai 's partnerships and industry decision-making and process Passionate about solving the industry leadership in next- adoption of LENS ai and HYFT OS. optimization. Information Integration Dilemma generation drug discovery. (IID) in biotechnology. République Capital NASDAQ:IPA | ir.ipatherapeutics.com | www.ipatherapeutics.com What is LENS ai ? Powered by HYFTs® - patented patterns that reveal unique and universal fingerprints across all biological data. Only HYFTs bring data together seamlessly. These patented patterns, inspired by evolution, link different types of data at the smallest level-unlocking insights that were previously impossible to see. HYFT technology searches through 440 million sequences across 11 major multi-omics databases in just 1 second- serious speed and unmatched efficiency in data analysis. NASDAQ:IPA | ir.ipatherapeutics.com | www.ipatherapeutics.com 25+ billion biologic connections revealing hidden insights 6 Why Now? Why Us? We alone hold the patents-the Rosetta Stone to interpret the language of life. Patented HYFT technology and applications granted in 29 countries worldwide and counting 15 years of tracking, mapping constellations of biological patterns, all embedded into the HYFT OS. Over 90 applications for fully in silico drug discovery - save years, save millions Over 25 HYFT Technology patents awarded worldwide NASDAQ:IPA | ir.ipatherapeutics.com | www.ipatherapeutics.com Advantage multiplied 7 Business Model "The HYFT system gives us a unique edge: it allows us to focus our compute resources only on the 2% of biological data that's truly actionable. That translates into faster insights, lower costs, and higher success rates-exactly the kind of leverage AI needs to transform biopharma at scale." "HYFT technology was built to solve a fundamental limitation in AI-its lack of native understanding of biological systems. By embedding structural, functional, and sequential logic into a unified index, we give AI models the context they need to reason through biology, not just compute it." "At BioStrand, we didn't set out to make AI fit biology-we built a biological framework that AI could natively understand. HYFT technology is more than a tool; it's a new language for interpreting life. GTC 2025 showed us that the world is ready for that shift-from data-driven guesses to biologically grounded intelligence." • - Dr. Dirk Van Hyfte, Co-Founder & Chief Innovation Officer, HYFT technology: built to solve a fundamental limitation in AI-its lack of native understanding of biological systems. BioStrand Market Opportunity: Unlocking Scalable Revenue with Bio-AI TAM (Total Addressable Market): AI in Drug Discovery TAM projected to exceed $50B by 2030. Biological data infrastructure (bio-native AI + data harmonization) is a key growth vertical. Life sciences data management: multi-billion dollar market (e.g., Informatica 25% share, $445M quarterly revenue). Our Vertical SaaS Opportunity: HYFT-powered data management and LENS ai 's AI modules. Scalable subscription models for biotech/pharma. Tiered API access, usage-based pricing, upsell to custom modules. >3,000 antibody programs and >300 antibody projects since 2020. Direct access to 95% of the top 20 global pharma as clients. Target Market Penetration: ~5% AI Drug Discovery market by 2028. 20-30 key partnerships across therapeutic areas. Repeatable revenue through renewals, upsells, and shared asset models. From Discovery to Revenue: Our Bio-AI Monetization Engine HYFT Index: Universal biological fingerprints-continuously enriched and powering deep biological understanding. LENS ai Platform: AI engine connecting sequence, structure, function, and literature into a unified reasoning layer. Monetization Pillars V-SaaS: Subscription-based access to specialized AI modules rooted in lossless harmonized data. Custom Research-as-a-Service: Partner-driven discovery programs using HYFT + LENS ai . Platform Licensing: API/SDK integration for enterprise discovery pipelines. Milestone-Based Collaborations: Co-developed assets with upside-sharing models. Customer-Facing Tools: Antibody design portals, target validation dashboards, and predictive APIs-all cloud-delivered and scalable. Data Management Layer: HYFT technology ensures lossless integration of multi-modal data into a single coherent graph. This is the foundation of our V-SaaS model: once data is harmonized and indexed by HYFTs, it becomes AI-ready-enabling LLMs, AI-Powered Wet Lab Integration: End-to-end drug discovery stack from target to IND. "HYFT and LENS ai aren't just technologies-they're revenue-generating engines built for scale. Our model combines the recurring revenue of SaaS with the strategic upside of biopharma partnerships." Dr. Dirk Van Hyfte, Co-Founder & Chief Innovation Officer, APIs, and applications to operate efficiently across biology's full spectrum. BioStrand Attention : This is an excerpt of the original content. To continue reading it, access the original document here . Attachments Original document Permalink Disclaimer ImmunoPrecise Antibodies Ltd. published this content on April 10, 2025 , and is solely responsible for the information contained herein. Distributed via , unedited and unaltered, on April 10, 2025 at 13:27 UTC . Evolving the Intersection of AI, Data and Biology for Drug Discovery. Spring 2025 | NASDAQ:IPA ©2025 ImmunoPrecise Antibodies LTD. All rights reserved. IPA is a trademark of ImmunoPreciseAntibodies LTD. BioStrand is an independently operating subsidiary of BioStrand, BV. LENS ai and HYFTS are trademarks of BioStrand, BV. Capital structure overview (all values in CAD unless otherwise noted) SHARE DATA (as of March 27, 2025, $ in USD) Shares Outstanding 45,765,118 Share Price USD $0.44 Market Cap USD $20,136,652 BALANCES (as of March 27, 2025) Unrestricted Cash $12.9 million FINANCIAL DATA ($ in 000's) Q3 FY25 FY24 FY23 Revenue (CRO) 17,539 24,518 20,665 Gross Margin 9,088 12,053 11,563 Cash Provided 9,601 (4,788) (22,421) (Used) WARRANTS (as of March 27, 2025) WEIGHTED WEIGHTED FUTURE CASH BALANCE AVERAGE AVERAGE LIFE OPPORTUNITY EXERCISE PRICE REMAINING (YRS) 130,111 $24.14 1.01 $3,140,880 56,650 $1.44 3.85 $81,576 OPTIONS (as of March 27, 2025) WEIGHTED WEIGHTED AVERAGE BALANCE AVERAGE LIFE EXERCISE REMAINING (YEARS) PRICE Exercisable 1,389,165 $7.50 2.66 Unvested 723,417 $1.39 8.88 Total 2,112,582 $5.41 4.79 NASDAQ:IPA | ir.ipatherapeutics.com | www.ipatherapeutics.com Partner with the best "We tried 7 different AI companies and could not validate any of the work, until IPA...we've validated 100% of the results from LENS ai " - Top 10 Global Pharma Partner "IPA is known for taking the toughest "LENS ai is the OpenAI of the life sciences. programs and knocking them out of the park" Every pharma company develops drugs. - Top 5 Global Pharma Partner IPA is the company that EVERYONE will use. - Multi-Billion Dollar Tech Partner IPA works with 19 of top 20 pharma - global partners include: NASDAQ:IPA | ir.ipatherapeutics.com | www.ipatherapeutics.com Leadership Jennifer Bath, Ph.D.: Frédéric Chabot: Dr. Ingrid Brands, MD, Ph.D.: Dr. Dirk Van Hyfte MD, Ph.D.: Chief Executive Officer Head Corp Development Co-Founder, BioStrand Co-Founder, BioStrand Visionary executive in Business strategist with Experienced leader in biotech Pioneering expert in AI-driven drug biotechnology and therapeutics, d